In an article in DRI’s For the Defense, Goodwin associate Alison Siedor dives into the distinct labeling requirements applicable to biosimilars. Challenges to meet these requirements could affect product liability litigation in this area, raising implications that are potentially distinct from those related to biologics and small-molecule generic drugs. Please click here to read the full article.
To stay up to date on developments in the biosimilars space, follow Goodwin’s award-winning blog, Big Molecule Watch.